摘要
目的:探讨恩格列净对改善2型糖尿病(T2DM)患者左心室重构的疗效。方法:我们在PubMed、EMBASE、Cochrane Library、Web of Science、CNKI数据库、VIP数据库、Wanfang数据库,共7个电子数据库中搜索了在2020年9月30日之前发表的文章,包括中文和英文。我们在分析中纳入了随机对照试验。评价治疗组与对照组左室超声心动图参数平均变化的差异。结果:Meta分析结果显示,LAVI (WMD = −6.29, 95%CI (−10, −2.58),P 【0.001), E/e′ (WMD = −2.15, 95%CI (−4.08, −0.21), P = 0.003), LVEF (WMD = 3.67, 95%CI (0.59, 6.75), P = 0.02), LVEDV (WMD = −1.99, 95%CI (−26.49, −22.50), P = 0.87), LVESV (WMD = −8.36, 95%CI (−17.36, −0.65), P = 0.07)。结论:恩格列净可显著降低2型糖尿病患者的LAVI和E/e′,改善患者心功能。
Objective: The purpose of this meta-analysis is to explore the efficacy of empagliflozin in improving left ventricular (LV) remodeling in patients with type 2 diabetes (T2DM). Methods: We searched articles published before September 30, 2020, Language including Chinese and English, in 7 electronic databases: PubMed, EMBASE, Cochrane Library, Web of Science, CNKI database, VIP database and Wanfang database. We included randomized controlled trials in this meta-analysis to evaluate the difference in mean changes in left ventricular echocardiographic parameters between the treatment and control groups. Results: The results of meta-analysis showed that LAVI (WMD = −6.29, 95%CI (−10, −2.58), P
出处
《临床医学进展》
2021年第2期469-475,共7页
Advances in Clinical Medicine
